A carregar...
Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases
Apatinib, an oral small molecular receptor tyrosine kinase inhibitor (TKI) developed first in China, exerts antiangiogenic and antineoplastic function through selectively binding and inhibiting vascular endothelial growth factor receptor 2 (VEGFR-2). In this study, we aimed to explore the efficacy a...
Na minha lista:
| Publicado no: | Oncol Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Cognizant Communication Corporation
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7851530/ https://ncbi.nlm.nih.gov/pubmed/31610827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504019X15707896762251 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|